Bio-Rad Laboratories, Inc.
BIO
Rang în acțiuni
#2155
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules,... Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Preț acțiune
$354.95
Capitalizare de piață
$9.49B
Schimbare (1 zi)
0.82%
Schimbare (1 an)
10.27%
Țară
US
Tranzacționează Bio-Rad Laboratories, Inc. (BIO)
Categorie
Healthcare
Raport P/E pentru Bio-Rad Laboratories, Inc. (BIO)
Raport P/E la data de October 2026 TTM: 43.51
Conform celor mai recente rapoarte financiare și prețului acțiunilor Bio-Rad Laboratories, Inc., raportul P/E actual (TTM) este 43.51. La sfârșitul anului 2023, compania avea un P/E de -14.80.
Istoricul raportului P/E pentru Bio-Rad Laboratories, Inc. din 2000 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | 43.51 | -964.99% |
| 2024 | -5.03 | -66.04% |
| 2023 | -14.80 | 328.61% |
| 2022 | -3.45 | -165.17% |
| 2021 | 5.30 | 16.45% |
| 2020 | 4.55 | -27.54% |
| 2019 | 6.28 | -67.28% |
| 2018 | 19.19 | -68.89% |
| 2017 | 61.69 | -67.67% |
| 2016 | 190.80 | 433.20% |
| 2015 | 35.78 | -8.68% |
| 2014 | 39.18 | -13.74% |
| 2013 | 45.42 | 158.67% |
| 2012 | 17.56 | 16.26% |
| 2011 | 15.11 | -2.48% |
| 2010 | 15.49 | -15.26% |
| 2009 | 18.28 | -19.87% |
| 2008 | 22.81 | -23.37% |
| 2007 | 29.77 | 41.23% |
| 2006 | 21.08 | 0.79% |
| 2005 | 20.91 | -3.29% |
| 2004 | 21.63 | 12.38% |
| 2003 | 19.24 | 34.25% |
| 2002 | 14.33 | -18.83% |
| 2001 | 17.66 | 41.42% |
| 2000 | 12.49 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 33.11 | -23.90% |
US
|
|
| 21.39 | -50.84% |
IE
|
|
| 28.94 | -33.47% |
US
|
|
| 17.34 | -60.15% |
US
|
|
| - | - |
DE
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.